Results of phase I clinical trial reported the efficacy of vaccination with dendritic cells (DC) loaded with a cocktail consisting of HLAA*0201-restricted peptides derived from five different PCa-associated antigens prostate-specific antigen (PSA), prostate-specific membrane antigen, survivin, prostein, and also an HLA-A*0201-restricted T cell epitope derived from the PCa-associated protein TRPM8 (TRPM8 187–195, GLMKYIGEV) [63]. The gene discussed is KLK3; the disease is posterior cortical atrophy.